<?xml version="1.0" encoding="UTF-8"?>
<p>The major contribution of 
 <italic>B. ligulata</italic> towards pharmaceutical applications is that of an antilithiatic agent. Lower dose (0.5 mg/kg) of the EtOH extract of 
 <italic>B. ligulata</italic> rhizome encourages diuresis in rats and is effective in dissolving preformed stones [
 <xref rid="B144-molecules-25-05555" ref-type="bibr">144</xref>]. The MeOH extracts of the rhizome also possess an antilitihiatic property that has been tested both in vitro and in vivo. In male Wistar rats, 5–10 mg/kg of the extract inhibited calcium oxalate crystal (CaC
 <sub>2</sub>O
 <sub>4</sub>•
 <sub>x</sub>) aggregation in the renal tubes. There are several other reports that state that 
 <italic>Bergenia</italic> extracts exerts its antilithiactic effect by diuresis, inhibition of CaC
 <sub>2</sub>O
 <sub>4</sub>•
 <sub>x</sub> crystal formation and aggregation, and hypermagnesemic and antioxidant activity [
 <xref rid="B106-molecules-25-05555" ref-type="bibr">106</xref>,
 <xref rid="B145-molecules-25-05555" ref-type="bibr">145</xref>,
 <xref rid="B146-molecules-25-05555" ref-type="bibr">146</xref>].
</p>
